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Abstract:
Introduction: The emergency department (ED) plays a critical role in the management
of life-threatening infection. Prior data suggest that ED vancomycin dosing is frequently
inappropriate.The objective is to assess the impact of an electronic medical record (EMR)
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intervention designed to improve vancomycin dosing accuracy, on vancomycin dosing and clinical
outcomes in critically ill ED patients.
Methods: Retrospective before-after cohort study of all patients (n=278) treated with vancomycin
in a 60,000-visit Midwestern academic ED (March 2008 and April 2011) and admitted to an
intensive care unit. The primary outcome was the proportion of vancomycin doses defined as
“appropriate” based on recorded actual body weight. We also evaluated secondary outcomes of
mortality and length of stay.
Results: The EMR dose calculation tool was associated with an increase in mean vancomycin
dose ([14.1±5.0] vs. [16.5±5.7] mg/kg, p<0.001) and a 10.3% absolute improvement in first-dose
appropriateness (34.3% vs. 24.0%, p=0.07). After controlling for age, gender, methicillin-resistant
staphylococcus aureus (MRSA) infection, and Acute Physiology and Chronic Health Evaluation II
(APACHE-II) score, 28-day in-hospital mortality (odds ratio OR 1.72; 95% CI [0.76-3.88], p=0.12)
was not affected.
Conclusion: A computerized decision-support tool is associated with an increase in mean
vancomycin dose in critically ill ED patients, but not with a statistically significant increase in
therapeutic vancomycin doses. The impact of decision-support tools should be further explored to
optimize compliance with accepted antibiotic guidelines and to potentially affect clinical outcome.
Supporting material:
Revised order in EMR. Providers see the recommended dose as the default value, and the
computer calculates a recommended first dose based on 20 mg/kg actual body weight with
maximum dose 2 grams.
Pre and Post intervention vancomycin administration and eligible patients for analysis flow
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Appropriateness of Vancomycin Dose by Patient Weight.
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Introduction: The emergency department (ED) plays a critical role in the management of lifethreatening infection. Prior data suggest that ED vancomycin dosing is frequently inappropriate.
The objective is to assess the impact of an electronic medical record (EMR) intervention designed
to improve vancomycin dosing accuracy, on vancomycin dosing and clinical outcomes in critically
ill ED patients.
Methods: Retrospective before-after cohort study of all patients (n=278) treated with vancomycin in
a 60,000-visit Midwestern academic ED (March 2008 and April 2011) and admitted to an intensive
care unit. The primary outcome was the proportion of vancomycin doses defined as “appropriate”
based on recorded actual body weight. We also evaluated secondary outcomes of mortality and
length of stay.
Results: The EMR dose calculation tool was associated with an increase in mean vancomycin
dose ([14.1±5.0] vs. [16.5±5.7] mg/kg, p<0.001) and a 10.3% absolute improvement in first-dose
appropriateness (34.3% vs. 24.0%, p=0.07). After controlling for age, gender, methicillin-resistant
staphylococcus aureus infection, and Acute Physiology and Chronic Health Evaluation II score, 28day in-hospital mortality (odds ratio OR 1.72; 95% CI [0.76-3.88], p=0.12) was not affected.
Conclusion: A computerized decision-support tool is associated with an increase in mean
vancomycin dose in critically ill ED patients, but not with a statistically significant increase in
therapeutic vancomycin doses. The impact of decision-support tools should be further explored to
optimize compliance with accepted antibiotic guidelines and to potentially affect clinical outcome.
[West J Emerg Med. 2015;16(4):557–564.]

INTRODUCTION
Vancomycin is a glycopeptide antibiotic that exhibits
time-dependent killing. It has been used for more than five
decades to treat resistant organisms, such as methicillinresistant Staphylococcus aureus (MRSA), and in the empiric
treatment for severe sepsis and septic shock. Efficacy is
Volume XVI, no. 4 : July 2015

often predicted by the ratio of the area under the antibiotic
concentration curve and the minimum inhibitory concentration
of the infecting pathogen (AUC/MIC ratio). An AUC/MIC
ratio of ≥400 with trough serum concentrations of 15-20mg/L
are recommended to achieve clinical effectiveness and
limit the development of resistant microorganisms.1 MRSA
557
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vancomycin treatment failures are occurring with increasing
frequency, and vancomycin-intermediate Staphylococcus
aureus (VISA) has emerged as a leading cause of vancomycin
failures and poor clinical outcomes.2-3
Inappropriate vancomycin dosing is associated with
the emergence of VISA.4-6 Conventional dosing practices
initiate vancomycin at 1000mg every 12 hours.7 Due to
the association of conventional dosing and subtherapeutic
vancomycin trough levels, however, current guidelines
advocate for weight-based dosing algorithms.1,8
The emergency department (ED) plays a critical role in
the management of life-threatening infection.9 There is also
an increased awareness of the ED’s role in antimicrobial
initiation, with an increased interest in antibiotic stewardship
beginning in the ED.10 ED antibiotic initiatives include
both appropriate usage and timely administration. Prior
data suggest that ED dosing of vancomycin is frequently
inappropriate, yet vancomycin administered in the ED is
often continued into the inpatient course.7,11 This suggests
that the ED is highly influential on overall antibiotic therapy,
regardless of dosing or indication appropriateness.7 This
practice pattern has the potential for developing antibiotic
resistance, as organisms such as VISA are invariably
associated with vancomycin exposure and subtherapeutic
dosing strategies.4
Appropriate antibiotic selection and dose optimization is
a prime determinant of outcome in critically ill patients.12 ED
clinical pharmacists improve appropriate antibiotic dosing,
yet fewer than 5% of EDs have an ED-based pharmacist.10,13
Therefore, an electronic medical record (EMR) based
antibiotic stewardship strategy could be a generalizable
intervention with a measurable effect on antibiotic selection
and dosing across many EDs in the community.
The primary objective of this analysis was to assess
the impact of an EMR intervention on vancomycin dosing
accuracy in critically ill ED patients. We hypothesized that an

EMR intervention would be associated with improvement in
vancomycin dosing accuracy. Secondary objectives were to
assess the impact of vancomycin dosing on mortality, hospital
length of stay, acute kidney injury, and the impact of obesity
on vancomycin dosing accuracy.
METHODS
Patients and Setting
This study was a retrospective before-after cohort study
(March 2008–May 2009 [before] and November 2009–April
2011 [after]) conducted in the ED of a Midwestern academic
Level I trauma center with an annual ED census of 60,000
patient visits.
Intervention
We included all patients treated with vancomycin in
the ED and admitted to an intensive care unit. For patients
who received vancomycin on multiple ED visits during the
study period (2%), only the first visit was included in the
analysis. The post-intervention period began after weightbased vancomycin dosing guidance was incorporated into
computerized physician order entry (CPOE) to correspond
to updated guidelines from the Infectious Diseases Society
of America in 2009.1,14 The EMR intervention included
an automatic dose calculation tool included in the CPOE
order, and an educational campaign (e-mail notification to
all EM staff and a presentation by a research team member
to EM residents and attending physicians) accompanied the
rollout. The automatic dose calculation tool recommended
a vancomycin dose of 20mg/kg actual body weight (as
recorded in the medical record). The calculated dose was
rounded to the nearest 250mg and did not recommend
greater than 2 gram in a single dose (Figure 1). A six-month
run-in period was excluded from analysis a priori to assure
that all providers had time to acclimate themselves to the
new automatic dose calculation tool.

Figure 1. Revised order in EMR. Providers see the recommended dose based on the computer calculation. The computer
recommended first dose is 20mg/kg actual body weight with maximum dose 2 grams.
EMR, electronic medical record; IDSA, Infectious Diseases Society of America; UHC, University Health System Consortium
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Data Abstraction
We abstracted vancomycin dosing and clinical variables
from the EMR using both database query and manual data
collection by two trained data abstractors (KD, BP). The two
data abstractors were blinded to the study hypothesis and
received formal training in proper data abstraction techniques.
After data abstraction, 15% of charts were randomly selected
for review by a third independent investigator (BAF) to
validate data accuracy and abstraction techniques. We defined
all variables a priori and recorded them in an electronic
database for analysis.
Definitions
Appropriate vancomycin dose was defined as 15-20mg/
kg in accordance with guideline recommendations.1 We
based obesity categorization on the definitions by the World
Health Organization as underweight (body mass index (BMI)
<18.5), normal (18.5-24.99), overweight (25.0-29.99) and
obese (≥30).15 Mortality was assessed at 28 days after hospital
admission. Subjects discharged alive before 28 days were
coded as alive. We defined acute kidney injury as increase
in serum creatinine by 0.3mg/dL within 48 hours or increase
to 1.5 times baseline.16 We calculated Acute Physiology and
Chronic Health Evaluation II (APACHE-II) scores based on
clinical data collected within 24 hours of hospital admission.
Parameters not recorded were imputed to be normal for the
purposes of APACHE-II calculation. Vancomycin levels were
collected during each patient’s hospital stay.
Outcomes
The primary outcome was the proportion of vancomycin

doses defined as “appropriate” based on recorded actual body
weight. Secondary outcomes included 28-day in-hospital
mortality, hospital length of stay and acute kidney injury
(safety outcome). We also measured the impact of obesity
and the sustained effect of the intervention (stratified in
four-month intervals). Overweight and obese patients who
received the maximum dose of 2 gram were categorized in the
“appropriate” group even though the calculator recommended
larger doses based on the actual weight.
We conducted univariate analysis using t-test, chisquared test, or ANOVA, as appropriate. Multivariable
logistic regression analysis was used to estimate the effect
of the EMR intervention on 28-day in-hospital mortality,
controlling for potentially confounding covariates (age,
sex, MRSA, BMI, APACHE II score, acute kidney injury,
vasopressor administration, mechanical ventilation and history
of hemodialysis). We prespecified variables included in the
model based on a priori knowledge and defined a statistical
threshold of p<0.20. Collinearity and statistical interactions
were measured. All tests were two-tailed and a p-value <0.05
was considered statistically significant. We conducted all
analyses using SAS® software (version 9.3, SAS System
for Microsoft, SAS Institute Inc., Cary, NC, USA). The
institutional review board approved the study protocol.
RESULTS
We included 278 subjects in the study (Figure 2).17
Baseline characteristics are shown in Table 1. Mean
vancomycin dose increased after the intervention ([14.1±5.0]
vs. [16.5±5.7]mg/kg, p<0.001). First-dose appropriateness
increased from 24.0% to 34.3%, p=0.07. Overall, 30.6%

Table 1. Patient demographics, outcomes and vancomycin dosing before and after an electronic medical record intervention.
EMR intervention
Total
Total, n(%)

Before

After

p-value

278

100 (36.0)

178 (64.0)

Age, y (SD)

57.2 (17.7)

57.5 (17.5)

57.1 (17.8)

0.85

Male, n(%)

172 (61.9)

58 (58.0)

114 (64.0)

0.32

BMI, kg/m (SD)

30.1 (13.1)

31.9 (18.8)

29.1 (9.0)

0.18

17.7 (5.3)

17.8 (5.4)

17.6 (5.2)

0.84

1253.6 (381.2)

1115 (283)

1331.5 (407)

<0.0001

mg/kg, mean (SD)

15.7 (5.6)

14.1 (5.0)

16.5 (5.7)

0.0003

Patients given 1 gram, n(%)

166 (59.7)

84 (84.0)

92 (51.7)

<0.0001

85 (30.6)

24 (24.0)

61 (34.3)

0.0745

2

APACHE II, score (SD)
Vancomycin dosing
Total, mean (SD)

Appropriate dose, n(%)
MRSA in culture, n(%)

29 (10.4)

5 (5.0)

24

0.03

Acute kidney injury, n(%)

90 (32.4)

34 (34.0)

56

0.66

40

10 (10.0)

30

0.12

28 day in-hospital mortality, n(%)

EMR, electronic medical record; APACHE, acute physiology and chronic health evaluation; MRSA, methicillin-resistant Staphylococcus
aureus; BMI, body mass index
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for age, sex, MRSA infection status, and APACHE-II, 28day mortality was not associated with the EMR intervention
(adjusted odds ratio 1.72 [0.76-3.88], p=0.12). The
intervention did not significantly increase the risk of acute
kidney injury in the post intervention group (34.0% vs. 31.5%,
p=0.66). The appropriateness of the vancomycin dose did not
have a significant effect on hospital length of stay for the preand post-intervention groups (Table 2).
Obesity had a significant effect on the appropriateness of
vancomycin dosing (Figure 3). Overweight (55.2% vs. 34.1%)
and obese (63.6% vs. 34.1%) subjects were more likely to be
underdosed (p<0.0001), and no underweight patients were
underdosed. Underweight patients were more like to receive
an inappropriately high dose than the normal weight patients
(72.7% vs. 28.6%, p<0.0001).
The prevalence of MRSA identified as an infectious agent
from a blood culture or bronchoalveolar lavage increased
between study periods from 5.0% to 13.5% (p=0.03). Among
subjects without MRSA, neither inappropriately low nor high
doses were associated with survival (Table 3).
Figure 2. Pre- and post-intervention vancomycin administration
and eligible patients for analysis flow diagram.
ICU, intensive care unit

of patients received an appropriate dose (Table 2). The
proportion of patients receiving a dose of 1g decreased (84%
vs. 52%, p<0.001). Vancomycin trough levels were obtained
in 157 patients (56%), and median trough levels did not
change during the study period (13.3, IQR [10.6-22.4]) vs.
13.8, IQR [9.4-18.3], p=0.59)
Twenty-eight day mortality (10.0% vs. 16.9%, p=0.12)
did not change with the intervention. In univariate analysis,
mortality was not associated with the intervention period
(Table 3). Using multivariable logistic regression to adjust

DISCUSSION
As a recommended therapy for critically ill patients with
life-threatening infection, vancomycin is frequently administered
in the ED. Although other investigators have examined the role
of vancomycin dosing on clinical outcomes, our study evaluated
systematically the effect of an EMR intervention on the clinical
outcome of patients admitted from the ED to an intensive care
unit. This is an important finding because it highlights both the
role of quality improvement initiatives and their unintended
consequences on clinical outcomes.
In our cohort, the EMR intervention increased the
dose of vancomycin (14.1±5.0mg/kg vs. 16.5±5.7mg/
kg, p<0.0001). The increase in the mean vancomycin dose
was relatively small; however, the proportion of patients
who received a dose recommended by Infectious Diseases

Table 2. Patient demographics and outcomes by appropriateness of vancomycin dose (n=278).
Appropriateness of vancomycin dose
Underdosed
(n=138)
Age, y (SD)
Male, n(%)

60.9 (16.1)

Correct
(n=85)

Overdosed
(n=55)

p-value

54.8 (16.8)

51.8 (20.7)

0.0015

93 (67.4)

41 (48.2)

38 (69.1)

0.0078

32.9 (12.9)

28.3 (9.2)

25.9 (16.8)

0.0015

APACHE II, score (SD)

18.2 (5.1)

17.1 (5.2)

17.1 (5.7)

0.22

Acute kidney injury, n(%)

47 (34.0)

28 (32.9)

15 (27.3)

0.66

Post-EMR intervention, n(%)

72 (52.2)

61 (71.8)

45 (81.8)

0.0001

11.5 (13.7)

11.2 (11.5)

9.5 (9.3)

0.56

18 (13.0)

13 (15.3)

9 (16.4)

0.81

BMI, kg/m2 (SD)

Length of stay, days (SD)
28 day in-hospital mortality, n(%)

APACHE, acute physiology and chronic health evaluation; EMR, electronic medical record; BMI, body mass index

Western Journal of Emergency Medicine

560

Volume XVI, no. 4 : July 2015

Faine et al.

Vancomycin Dosing

Table 3. Unadjusted and adjusted odds of 28-day in-hospital mortality among patients receiving vancomycin (n=278) and adjusted odds
of 28-day in-hospital mortality among those without methicillin-resistant Staphylococcus aureus (MRSA).
28-day in-hospital mortality
No1
Yes2
n (%)
n (%)
56.0 [17.5]
64.7 [17.1]

p-value3
0.0040

OR (95% CI)
1.03 (1.01-1.05)

Adjusted OR (95% CI)5
1.03 (1.01-1.06)

Age, y [SD]
Sex
Female
96 (40.3)
10 (25.0)
0.06
1.0 (ref)
1.0 (ref)
Male
142 (59.7)
30 (75.0)
2.03 (0.95-4.34)
2.29 (1.02-5.14)
MRSA
No
213 (89.5)
36 (90.0)
0.92
1.0 (ref)
1.0 (ref)
Yes
25 (10.5)
4 (10.0)
0.95 (0.31-2.89)
0.76 (0.24-2.41)
0.98 (0.94-1.02)
BMI, kg/m2 [SD]
0.47
30.4 [11.8]
28.1 [19.4]
SBP, mmHg [SD]
115.7 [29.3]
113.9 [34.6]
0.73
1.0 (0.99-1.01)
APACHE II, score [SD]
17.4 [5.4]
19.2 [4.4]
0.05
1.07 (1.00-1.14)
1.04 (0.96-1.11)
Acute kidney injury
No
165 (69.3)
23 (57.5)
0.14
1.0 (ref)
Yes
73 (30.7)
17 (42.5)
1.67 (0.84-3.31)
Vasopressors
No
213 (89.5)
33 (82.5)
0.20
1.0 (ref)
Yes
25 (10.5)
7 (17.5)
1.81 (0.72-4.51)
Intubation
No
201 (84.5)
29 (72.5)
0.06
1.0 (ref)
Yes
37 (15.5)
11 (27.5)
2.06 (0.95-4.48)
History of dialysis
No
221 (92.9)
39 (97.5)
0.494
Unable to calc
Yes
17 (7.1)
1 (2.5)
Post-EMR intervention
No
90 (37.8)
10 (25.0)
0.12
1.0 (ref)
1.0 (ref)
Yes
148 (62.2)
30 (75.0)
1.82 (0.85-3.91)
1.72 (0.76-3.88)
Appropriate vancomycin
dose
Underdosed
120 (50.4)
18 (45.0)
0.81
0.83 (0.38-1.80)
0.60 (0.26-1.41)
Correct
72 (30.3)
13 (32.5)
1.0 (ref)
1.0 (ref)
Overdosed
46 (19.3)
9 (22.5)
1.08 (0.43-2.74)
0.88 (0.33-2.37)
Vancomycin dosing
Total, mean [SD]
1260.5 [384.8]
1212.5 [360.5]
0.46
1.0 (0.999-1.001)
Mg/kg, mean [SD]
15.5 [5.6]
16.6 [5.2]
0.24
1.04 (0.98-1.10)
APACHE, acute physiology and chronic health evaluation; EMR, electronic medical record; BMI, body mass index
Brackets denotes standard deviation. Parenthesis denotes percentage.
1
n=238.
2
n=40.
3
Chi-square test for categorical variables and student’s t-test for continuous variables.
4
Fisher’s exact test.
5
Model is adjusted for all variables that have an adjusted odds ratio reported.

Society of America (IDSA) guidelines increased in the postintervention group. Sixty-six percent of patients received a
dose recommended by the algorithm but outside the IDSArecommended vancomycin range because the rounding pushed
doses inappropriately high for some patients. Even though
we decreased “traditional” (1 gram) dosing, a button on the
vancomycin order still permitted easy prescribing of this dose,
so the rate of traditional dosing still remained over 50%.
Volume XVI, no. 4 : July 2015

The only clinical predictor that had a significant effect
on vancomycin dosing in the post-intervention group was
patient weight. Overweight and obese patients were more
likely to be underdosed. This occurred even with our analysis
categorizing overweight and obese patients as receiving the
“appropriate” dose if they received the maximum 2 gram
dose even though the calculator recommended a higher
dose based on their actual body weight. Another factor
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Figure 3. Appropriateness of vancomycin dose by patient weight.

contributing to underdosing may be the fear of nephrotoxicity.
A main objective of vancomycin dosing is to achieve
therapeutic trough levels rapidly. A recent meta-analysis
reported the incidence of nephrotoxicity between 5% and
43%, and suggested that the rate is low without concomitant
administration of other nephrotoxins.18 In our patient
population, increased patient weights led to unreliable dosing.
The EMR intervention increased the dose of
vancomycin but failed to have significant effects on clinical
outcomes. The increased dose in the post-intervention
group did not have a significant effect on mortality, hospital
length of stay or increase the risk of acute kidney injury.
There was a trend towards increased mortality in the postintervention group (as reported in a prior study) but this did
not reach statistical significance.7
One of the most speculative aspects of our study is the
association of mortality with a change in drug dosing. A
prior study suggested that higher vancomycin dosing was
associated with higher mortality.7 Two interpretations of
this observation are possible: either sicker patients were
treated with higher doses (bias), or vancomycin actually
impairs survival among patients without vancomycintreated infection. Interestingly, most reports of increased
effectiveness of aggressive vancomycin dosing enroll only
patients with documented vancomycin-susceptible infection
(e.g., MRSA).8,20 If vancomycin improves survival among
MRSA patients but harms patients without MRSA, the
population prevalence of MRSA would be the primary
determinant of effectiveness in a study. Furthermore, such
Western Journal of Emergency Medicine

a model would suggest that vancomycin only benefits
population survival if the local incidence of MRSA exceeds
a threshold. Although our study does not confirm the
prior finding, it was not powered to detect a difference in
mortality.7 The nonsignificant effect estimate, however,
closely mirrors the effect size of increased mortality with
higher vancomycin dosing in the previous study. The beforeafter methodology of this analysis better limits the potential
for bias. Based on these data, it is imperative that real time
diagnostics are developed to avoid exposure to unnecessary
therapies in critically ill patients.
Instituting an EMR intervention can significantly decrease
dosing errors and improve compliance with recommended
dosing.21 However, EMR interventions can also have
unintended consequences, including dosing errors. An
unintended effect of our intervention was that it increased
the proportion of patients receiving a dose higher than
recommended. Fortunately, the higher doses did not result
in an increase in adverse events. In our study, administering
modestly higher doses did not increase acute kidney injury,
but inpatient dosing regimens were not characterized.
LIMITATIONS
Our study has several important limitations. First,
this was a retrospective data analysis, which introduces
a risk of bias due to poor documentation or incomplete
information. We selected variables that would have been
available at the time of the ED visit and were likely to
be documented accurately in the EMR. Even with these
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measures, some relevant factors may not have been
captured. Second, our study was carried out at a single
center with a relatively low risk of MRSA. The prevalence
of MRSA in our study did increase between study periods,
which is consistent with other reports in the United States.22
Since the primary outcome was provider behavior, our
findings are likely valid.6 Third, we used a run-in design
which excluded a six-month time frame used for education
for the EMR intervention and a systematic shift to weightbased dosing. By excluding this time frame we could
have underestimated early adverse effects of the clinical
change. Fourth, we were unable to gauge appropriateness
of the indication for vancomycin in our ED. One study
evaluated the appropriateness of vancomycin in the ED
and found that 40% of the patients in the study did not
warrant vancomycin administration.6 Last, based on the
recommendations from the IDSA clinical practice guideline
for the treatment of MRSA, we elected to cap the dose of
vancomycin at 2 grams for all patients in the intervention
group.14 Vancomycin pharmacokinetics (volume of
distribution, protein binding, and clearance) can be altered
in obese patients; however, the variability does not mean
that obese patients require higher total daily doses to attain
target trough concentrations.23-24
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